VALENZABIO
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases. ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.
VALENZABIO
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Bethesda, Maryland, United States
Country:
United States
Website Url:
http://www.valenzabiotech.com
Status:
Active
Contact:
212 945 8929
Total Funding:
93.87 M USD
Technology used in webpage:
Google Tag Manager WordPress Global Site Tag Nginx DoubleClick.Net WP Engine Material Design For Bootstrap
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with superior immune cell therapies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Legacy Healthcare
Legacy Healthcare is developping safer drugs for the treatment of autoimmune and inflammatory diseases in fragile patients
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Vibliome
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
XellSmart
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Current Employees Featured
Founder
Investors List
Pierre Fabre
Pierre Fabre investment in Series A - ValenzaBio
Ikarian Capital
Ikarian Capital investment in Series A - ValenzaBio
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series A - ValenzaBio
Surveyor Capital
Surveyor Capital investment in Series A - ValenzaBio
Opaleye Management
Opaleye Management investment in Series A - ValenzaBio
Janus Henderson Investors
Janus Henderson Investors investment in Series A - ValenzaBio
Official Site Inspections
http://www.valenzabiotech.com Semrush global rank: 5.71 M Semrush visits lastest month: 1.47 K
- Host name: 104.21.44.134
- IP address: 104.21.44.134
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
